GW Pharmaceuticals PLC- (GWPH) Receives Average Recommendation of “Hold” from Analysts

GW Pharmaceuticals PLC- (NASDAQ:GWPH) has earned an average recommendation of “Hold” from the twelve analysts that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $152.50.

Several research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a research note on Tuesday, December 26th. BidaskClub raised shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. Goldman Sachs Group raised shares of GW Pharmaceuticals PLC- from a “neutral” rating to a “buy” rating and set a $174.00 price objective on the stock in a research note on Thursday, December 14th. Cantor Fitzgerald set a $208.00 price objective on shares of GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research note on Monday, December 4th. Finally, Bank of America reduced their price objective on shares of GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating on the stock in a research note on Tuesday, November 14th.

A number of hedge funds have recently made changes to their positions in GWPH. BNP Paribas Arbitrage SA acquired a new stake in GW Pharmaceuticals PLC- during the 2nd quarter worth approximately $163,000. Wells Fargo & Company MN raised its holdings in GW Pharmaceuticals PLC- by 21.8% during the 2nd quarter. Wells Fargo & Company MN now owns 13,962 shares of the biopharmaceutical company’s stock worth $1,399,000 after buying an additional 2,500 shares during the period. Ameriprise Financial Inc. raised its holdings in GW Pharmaceuticals PLC- by 8.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 162 shares during the period. Advisor Group Inc. raised its holdings in GW Pharmaceuticals PLC- by 10.7% during the 2nd quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 145 shares during the period. Finally, Stifel Financial Corp raised its holdings in GW Pharmaceuticals PLC- by 24.4% during the 2nd quarter. Stifel Financial Corp now owns 18,716 shares of the biopharmaceutical company’s stock worth $1,885,000 after buying an additional 3,676 shares during the period. Hedge funds and other institutional investors own 74.57% of the company’s stock.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) opened at $132.42 on Friday. GW Pharmaceuticals PLC- has a one year low of $92.65 and a one year high of $140.52. The firm has a market cap of $3,360.00, a P/E ratio of -18.32 and a beta of 2.65. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.47 and a current ratio of 7.59.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings data on Monday, December 4th. The biopharmaceutical company reported ($2.18) earnings per share for the quarter, missing the consensus estimate of ($1.73) by ($0.45). GW Pharmaceuticals PLC- had a negative return on equity of 40.42% and a negative net margin of 1,607.85%. analysts forecast that GW Pharmaceuticals PLC- will post -7.83 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/20/gw-pharmaceuticals-plc-gwph-receives-average-recommendation-of-hold-from-analysts.html.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply